SSB
MBRX icon

Sandy Spring Bank’s Moleculin Biotech MBRX Stock Holding History

Sandy Spring Bank’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$87 Hold
4
– – ﹤0.01% 1190
2024
Q4 		$152 Hold
4
– – ﹤0.01% 1175
2024
Q3 		$253 Hold
4
– – ﹤0.01% 1145
2024
Q2 		$314 Hold
4
– – ﹤0.01% 1201
2024
Q1 		$526 Hold
4
– – ﹤0.01% 1148
2023
Q4 		$1.15K Buy
+4
New +$830 ﹤0.01% 1059

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Sandy Spring Bank's MBRX Position: Q1 2025 in Review

Sandy Spring Bank held its Moleculin Biotech (MBRX) position steady in Q1 2025 at 4 shares worth $87. The position accounts for ﹤0.01% of the portfolio, ranked #1190.

Sandy Spring Bank first reported a position in MBRX in Q4 2023 and has held it in 6 quarters since. The position peaked at $1.15K in Q4 2023. 22 funds tracked by Wall St. Rank hold MBRX as of Q1 2025.

  • Sandy Spring Bank held 4 shares of Moleculin Biotech worth $87 as of Q1 2025.
  • Sandy Spring Bank left its Moleculin Biotech share count unchanged in Q1 2025.
  • Moleculin Biotech made up ﹤0.01% of Sandy Spring Bank's portfolio in Q1 2025, its #1190 holding.
  • Sandy Spring Bank first reported a position in Moleculin Biotech in Q4 2023 and has held it in 6 quarters since.
  • Sandy Spring Bank's Moleculin Biotech position peaked at $1.15K in Q4 2023.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2025.

Based on Sandy Spring Bank's 13F filing for Q1 2025, filed 12 May 2025.